The European Hematology Association (EHA) Hybrid Congress will take place on June 8-15, 2023 in Francfurt, Germany
Cellectis will present, in a poster session, updated clinical and translational data on its BALLI-01 clinical trial (evaluating UCART22) in patients with relapsed/refractory B-cell acute lymphoblastic Leukemia (r/r B-ALL).
Title: Updated Results of the Phase I BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CAR-T Cell Product, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Presenter: Nicolas Boissel, M.D., Ph.D., Hôpital St Louis, Assistance Publique - Hôpitaux de Paris, Paris, France
A copy of the abstract is available on the EHA website here: https://library.ehaweb.org/eha/2023/eha2023-congress/385856/nicolas.boissel.updated.results.of.the.phase.i.balli-01.trial.of.ucart22.an.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Ac_id%3D385856
June 08, 2023
‐ June 15, 2023